Detailed information for compound 286520

Basic information

Technical information
  • TDR Targets ID: 286520
  • Name: 4-[3-(3,4-difluorophenyl)-5,5-dimethyl-4-oxof uran-2-yl]benzenesulfonamide
  • MW: 379.378 | Formula: C18H15F2NO4S
  • H donors: 1 H acceptors: 3 LogP: 2.68 Rotable bonds: 3
    Rule of 5 violations (Lipinski): 1
  • SMILES: O=C1C(=C(OC1(C)C)c1ccc(cc1)S(=O)(=O)N)c1ccc(c(c1)F)F
  • InChi: 1S/C18H15F2NO4S/c1-18(2)17(22)15(11-5-8-13(19)14(20)9-11)16(25-18)10-3-6-12(7-4-10)26(21,23)24/h3-9H,1-2H3,(H2,21,23,24)
  • InChiKey: PNYFNOIRFKMXNL-UHFFFAOYSA-N  


Substructure search Similarity search

Network

Hover on a compound node to display the structore

Synonyms

  • 4-[3-(3,4-difluorophenyl)-5,5-dimethyl-4-oxo-2-furyl]benzenesulfonamide
  • 4-[3-(3,4-difluorophenyl)-5,5-dimethyl-4-oxo-furan-2-yl]benzenesulfonamide
  • 4-[3-(3,4-difluorophenyl)-4-keto-5,5-dimethyl-2-furyl]benzenesulfonamide

Targets

Known targets for this compound

Species Target name Source Bibliographic reference
Mus musculus prostaglandin-endoperoxide synthase 2 Starlite/ChEMBL References
Mus musculus prostaglandin-endoperoxide synthase 1 Starlite/ChEMBL References

Predicted pathogen targets for this compound

By orthology
No druggable targets predicted by orthology data
By sequence similarity to non orthologous known druggable targets
No druggable targets predicted by sequence similarity
Obtained from network model

Ranking Plot

Putative Targets List

Species Potential target Raw Global Species
Schistosoma mansoni ADAM17 peptidase (M12 family) 0.0181 0.0194 1
Wolbachia endosymbiont of Brugia malayi peptide deformylase 0.4323 1 0.5
Echinococcus granulosus matrix metallopeptidase 7 M10 family 0.0359 0.0616 1
Toxoplasma gondii hypothetical protein 0.4323 1 0.5
Loa Loa (eye worm) matrixin family protein 0.0239 0.0332 0.4985
Trypanosoma brucei Polypeptide deformylase 1 0.1649 0.3671 0.5
Trypanosoma cruzi Peptide deformylase 2, putative 0.1649 0.3671 0.5
Onchocerca volvulus Matrilysin homolog 0.0219 0.0285 1
Echinococcus multilocularis adam 17 protease 0.0181 0.0194 0.2739
Brugia malayi Matrix metalloprotease, N-terminal domain containing protein 0.012 0.0051 0.1537
Plasmodium falciparum peptide deformylase 0.4323 1 0.5
Leishmania major polypeptide deformylase-like protein, putative 0.1649 0.3671 0.5
Schistosoma mansoni hypothetical protein 0.014 0.0098 0.5038
Loa Loa (eye worm) matrixin family protein 0.0219 0.0285 0.4282
Onchocerca volvulus Matrix metalloproteinase homolog 0.0219 0.0285 1
Treponema pallidum polypeptide deformylase (def) 0.4323 1 0.5
Echinococcus granulosus adam 17 protease 0.0199 0.0237 0.3473
Mycobacterium leprae PROBABLE POLYPEPTIDE DEFORMYLASE DEF (PDF) (FORMYLMETHIONINE DEFORMYLASE) 0.4323 1 1
Plasmodium vivax peptide deformylase, putative 0.4323 1 0.5
Mycobacterium tuberculosis Probable polypeptide deformylase Def (PDF) (formylmethionine deformylase) 0.4323 1 1
Brugia malayi Matrixin family protein 0.0239 0.0332 1
Mycobacterium ulcerans peptide deformylase 0.4323 1 1
Loa Loa (eye worm) hypothetical protein 0.012 0.0051 0.0766
Trypanosoma cruzi polypeptide deformylase-like protein, putative 0.1649 0.3671 0.5
Brugia malayi Hemopexin family protein 0.014 0.0098 0.2947
Trypanosoma brucei Peptide deformylase 2 0.1649 0.3671 0.5
Trypanosoma cruzi Peptide deformylase 2, putative 0.1649 0.3671 0.5
Trypanosoma cruzi polypeptide deformylase-like protein, putative 0.1649 0.3671 0.5
Onchocerca volvulus 0.014 0.0098 0.3431
Loa Loa (eye worm) hypothetical protein 0.038 0.0665 1
Echinococcus multilocularis matrix metallopeptidase 7 (M10 family) 0.0359 0.0616 1

Activities

Activity type Activity value Assay description Source Reference
IC50 (binding) = 0.0067 ug ml-1 Inhibition of COX2 in C57BL/6 mouse peritoneal macrophages assessed as reduction in PGE2 formation pre-incubated for 2 hrs before LPS stimulation for 16 hrs followed by arachidonic acid addition and measured after 10 mins in presence of 500 uM aspirin by radio-immuno assay or enzyme-immunoassay PATENT. No reference
IC50 (binding) = 0.007 ug ml-1 In vitro inhibitory activity against prostaglandin G/H synthase 2 using mouse peritoneal macrophage method ChEMBL. 14761182
IC50 (binding) = 0.007 ug ml-1 In vitro inhibitory activity against prostaglandin G/H synthase 2 using mouse peritoneal macrophage method ChEMBL. 14761182
IC50 (binding) = 1.9 ug ml-1 In vitro inhibitory activity against prostaglandin G/H synthase 1 using mouse peritoneal macrophage method ChEMBL. 14761182
IC50 (binding) = 1.9 ug ml-1 In vitro inhibitory activity against prostaglandin G/H synthase 1 using mouse peritoneal macrophage method ChEMBL. 14761182
IC50 (binding) = 1.94 ug ml-1 Inhibition of COX1 in C57BL/6 mouse peritoneal macrophages assessed as reduction in PGE2 formation pre-incubated for 2 hrs followed by arachidonic acid addition and measured after 10 mins by radio-immuno assay or enzyme-immunoassay PATENT. No reference
Selectivity (binding) = 290 Selectivity of the compound against COX-2 over COX-1 ChEMBL. 14761182
Selectivity (binding) = 290 Selectivity of the compound against COX-2 over COX-1 ChEMBL. 14761182

Phenotypes

Whole-cell/tissue/organism interactions

We have no records of whole-cell/tissue assays done with this compound What does this mean?

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

Bibliographic References

1 literature reference was collected for this gene.

If you have references for this compound, please enter them in a user comment (below) or Contact us.